|
|
|
|
|
|
|
M T W Thu F |
|
30 July, 2026 |
|
|
sponsored by
|
|
|
|
Strategic Solutions for Cost, Time, and Quality Challenges in Drug Development
|
| In today’s competitive pharmaceutical landscape, successfully advancing a drug candidate from discovery to commercialization requires a strategic balance of cost, time, and quality. Each decision along the development pathway can impact timelines, budgets, and ultimately, the quality and safety of the final product. Watch as a group of Cambrex experts shares actionable insights and proven strategies for navigating these critical trade-offs. |
|
|
|
|
|
|
|
|
|
|
|
|
|
In our office, we’re calling it the earnings-palooza. By our count, at least eight pharma companies released their earnings this morning, announcing pipeline cuts and — in the case of Sanofi and UCB — laying out a new vision.
Alnylam had the darkest day of the bunch. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
Yvonne Greenstreet, Alnylam CEO (Benjamin Fanjoy/Bloomberg via Getty Images) |
|
|
|
by Max Gelman
|
Alnylam’s second-quarter earnings report Thursday did little to assuage investor concerns in what has already been a difficult year for the company. The drugmaker lowered... | |
|
|
|
 |
|
|
|
by Ayisha Sharma
|
Three months into her role as CEO at Sanofi, Belén Garijo gave some insight on how she plans to boost the French company’s mid- to... | |
|
|
|
|
|
|
|
